TY - JOUR
T1 - CCR5/Δccr5 heterozygosity
T2 - A selective pressure for the syncytium- Inducing human immunodeficiency virus type 1 phenotype
AU - D'Aquila, Richard T.
AU - Sutton, Lorraine
AU - Savara, Anu
AU - Hughes, Michael D.
AU - Johnson, Victoria A.
N1 - Funding Information:
Received 4 September 1997; revised 24 November 1997. Financial support: NIH (AI-29193, AI-36611, AI-27659, AI-32775, AI-32794, AI-40876) and Boehringer Ingelheim Pharmaceuticals for some virology studies. Reprints or correspondence: Dr. Richard T. D'Aquila, Infectious Disease Unit and AIDS Research Center, Massachusetts General Hospital, 149 13th St., Charlestown, MA 02129 (daquila@helix.mgh.harvard.edu). * Other team members are listed after the text.
PY - 1998
Y1 - 1998
N2 - Mechanisms underlying the delay in dominance of syncytium-inducing (SI) phenotype HIV-1 (human immunodeficiency virus type 1) in vivo are unknown. Both random mutational events and selective pressures operative only late in the disease process have been suggested to underlie the shift from CCR5 to alternative coreceptor usage. Among the moderately advanced patients who entered AIDS Clinical Trials Group protocol 241, SI vital phenotype was more common among CCR5/Δccr5 heterozygotes (7/7, 100%) than among CCR5/CCR5 homozygotes (29/88, 33%; P < .001, Fisher's exact test). Other characteristics did not differ at study entry by CCR5 genotype, including median CD4 cell counts, plasma RNA levels, and infectious HIV-I titers in circulating cells. These data indicate that CCR5/Δccr5 heterozygosity, which decreases cell-surface levels of CCR5 available to serve as an HIV-1 entry coreceptor, is a selective pressure for evolution of T cell line-tropic viruses that use an alternative coreceptor.
AB - Mechanisms underlying the delay in dominance of syncytium-inducing (SI) phenotype HIV-1 (human immunodeficiency virus type 1) in vivo are unknown. Both random mutational events and selective pressures operative only late in the disease process have been suggested to underlie the shift from CCR5 to alternative coreceptor usage. Among the moderately advanced patients who entered AIDS Clinical Trials Group protocol 241, SI vital phenotype was more common among CCR5/Δccr5 heterozygotes (7/7, 100%) than among CCR5/CCR5 homozygotes (29/88, 33%; P < .001, Fisher's exact test). Other characteristics did not differ at study entry by CCR5 genotype, including median CD4 cell counts, plasma RNA levels, and infectious HIV-I titers in circulating cells. These data indicate that CCR5/Δccr5 heterozygosity, which decreases cell-surface levels of CCR5 available to serve as an HIV-1 entry coreceptor, is a selective pressure for evolution of T cell line-tropic viruses that use an alternative coreceptor.
UR - http://www.scopus.com/inward/record.url?scp=0031781607&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031781607&partnerID=8YFLogxK
U2 - 10.1086/515307
DO - 10.1086/515307
M3 - Article
C2 - 9607832
AN - SCOPUS:0031781607
SN - 0022-1899
VL - 177
SP - 1549
EP - 1553
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 6
ER -